Cargando…
A Mechanistic Investigation on the Anticancer Properties of SYA013, a Homopiperazine Analogue of Haloperidol with Activity against Triple Negative Breast Cancer Cells
[Image: see text] Triple-negative breast cancer (TNBC) is one of the most malignant cancers associated with early metastasis, poor clinical prognosis, and high recurrence rate. TNBC is a distinct subtype of breast cancer that lacks estrogen receptor (ER), progesterone receptor (PR), and human epider...
Autores principales: | Asong, Gladys M., Amissah, Felix, Voshavar, Chandrashekhar, Nkembo, Augustine T., Ntantie, Elizabeth, Lamango, Nazarius S., Ablordeppey, Seth Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774091/ https://www.ncbi.nlm.nih.gov/pubmed/33403252 http://dx.doi.org/10.1021/acsomega.0c03495 |
Ejemplares similares
-
An Evaluation of the Anticancer Properties of SYA014, a Homopiperazine-Oxime Analog of Haloperidol in Triple Negative Breast Cancer Cells
por: Asong, Gladys M., et al.
Publicado: (2022) -
The antiangiogenic effects of polyisoprenylated cysteinyl amide inhibitors in HUVEC, chick embryo and zebrafish is dependent on the polyisoprenyl moiety
por: Nkembo, Augustine T., et al.
Publicado: (2016) -
Polyisoprenylated cysteinyl amide inhibitors disrupt actin cytoskeleton organization, induce cell rounding and block migration of non-small cell lung cancer
por: Ntantie, Elizabeth, et al.
Publicado: (2017) -
Suppression of focal adhesion formation may account for the suppression of cell migration, invasion and growth of non-small cell lung cancer cells following treatment with polyisoprenylated cysteinyl amide inhibitors
por: Ntantie, Elizabeth, et al.
Publicado: (2018) -
Enantiomeric Separation,
Absolute Configuration by
X-ray Crystallographic Analysis, and Functional Evaluation
of Enantiomers of the Dual Ligand, SYA0340 at 5-HT(1A) and 5-HT(7A) Receptors
por: Bricker, Barbara A., et al.
Publicado: (2023)